Heidarian examined the dose‐dependent effects of carvacrol in human prostate cancer cell lines, which significantly reduced IL‐6 gene expression as compared to the control group in which IL‐6 protein reduced 41.5% and 52.7% at 360 and 420 μM. The gene discussed is IL6; the disease is Familial prostate cancer.